Last Update: Jul 16, 2026 Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Contemporary Patients With Metastatic Castration-Resistant Prostate Cancer in the PRECISION Data Platform ClinicalTrials.gov Identifier: [NCT07677254](https://clinicaltrials.gov/ct2/show/NCT07677254) Novartis Reference Number:CAAA617A0US04 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform. Condition Prostatic Neoplasms, Castration-Resistant Overall Status Recruiting Number of Participants17111 Start Date Jun 30, 2026 Completion Date Nov 30, 2026 Gender Male Age(s) 18 Years - 115 Years (Adult, Older Adult) ## Eligibility Criteria Inclusion criteria: \* Diagnosis of mCRPC between 01 January 2021 and 31 December 2025. \* Male sex at index, where index is the date of initial mCRPC diagnosis. \* Age 18 years at index. Exclusion criteria: • None United States #### Novartis Recruiting East Hanover,New Jersey,07936,United States ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: